Relative abundance of immune cells in control and reporter-expressing mice with DTx administration in different contexts . (A) Relative abundance of different immune populations as a percentage of CD45⁺ cells in Mrc1^{LSL-Venus-DTR} (WT; red) and Csf1r^Cre; CD206^{LSL-Venus-DTR} (DTR; blue) mice with B78chOVA tumor injection (day −5), OT-I adoptive transfer (day 0) and harvest (day 14) without DTx administration. (B and C) Relative abundance of different immune populations as a percentage of live cells with (B) late and (C) early depletion regimens by DTx treatment in B78chOVA tumors. (D) Schematic representation of the experimental setup for analysis of skin in Mrc1^{LSL-Venus-DTR} (WT; red) and Csf1r^Cre; Mrc1^{LSL-Venus-DTR} (DTR; blue) mice with DTx administration. (E) Relative abundance of different immune populations in the skin as a percentage of live cells. (F) Schematic representation of the experimental setup for B78chOVA tumor injection, OT-I T cell adoptive transfer, and early DTx administration with either isotype control or anti-Ly6G antibody treatment and analysis. (G and H) Abundance of different immune populations as (G) cells per g of tumor and (H) percentage of CD45⁺ cells in WT and DTR mice in the above experiment. (I) Abundance of CD44⁺CD103⁺CD69⁺ tissue-resident memory-like cells in B78chOVA tumors at day 18 in the early depletion setting. (J–M) In early DTx administration setting in WT (red; Mrc1^{LSL-Venus-DTR}) and DTR^L (blue; Lyz2(LysM)^Cre; Mrc1^{LSL-Venus-DTR}) mice, relative abundance of (J) TAMs and CD206⁺ TAMs, (K) cDC2, (L) neutrophils, and (M) monocytes. (N) Number of CD8 T cells and NK cells per B78chOVA tdLN from WT and DTR mice at endpoint of early DTx treatment. Bar graphs show mean ± SEM; data are representative of at least two independent experiments, each with at least three biological replicates per group. ****P < 0.0001, **P < 0.01, *P < 0.05, ns = no significance by Student’s t tests or Mann–Whitney test (A–C, E, and I–N), or Kruskal–Wallis test with post-hoc test correcting for false discovery (G and H).